CN1679593A - Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E - Google Patents
Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E Download PDFInfo
- Publication number
- CN1679593A CN1679593A CN 200510052256 CN200510052256A CN1679593A CN 1679593 A CN1679593 A CN 1679593A CN 200510052256 CN200510052256 CN 200510052256 CN 200510052256 A CN200510052256 A CN 200510052256A CN 1679593 A CN1679593 A CN 1679593A
- Authority
- CN
- China
- Prior art keywords
- linolenic acid
- alpha
- vitamin
- lecithin
- soybean phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 title claims abstract description 87
- 229960004488 linolenic acid Drugs 0.000 title claims abstract description 46
- 235000020661 alpha-linolenic acid Nutrition 0.000 title claims abstract description 45
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims description 36
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 title claims description 23
- 239000008347 soybean phospholipid Substances 0.000 title claims description 21
- 229930003427 Vitamin E Natural products 0.000 title claims description 18
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims description 18
- 235000019165 vitamin E Nutrition 0.000 title claims description 18
- 229940046009 vitamin E Drugs 0.000 title claims description 18
- 239000011709 vitamin E Substances 0.000 title claims description 18
- 239000002253 acid Substances 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000002131 composite material Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 239000007901 soft capsule Substances 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract description 27
- 235000010445 lecithin Nutrition 0.000 abstract description 27
- 239000000787 lecithin Substances 0.000 abstract description 27
- 229940067606 lecithin Drugs 0.000 abstract description 27
- 235000019197 fats Nutrition 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 208000004930 Fatty Liver Diseases 0.000 abstract description 4
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 4
- 208000010706 fatty liver disease Diseases 0.000 abstract description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 4
- 206010012289 Dementia Diseases 0.000 abstract description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 206010039966 Senile dementia Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 230000002265 prevention Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 4
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 4
- 229960002733 gamolenic acid Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 229940083466 soybean lecithin Drugs 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000271042 Gloydius halys Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000272041 Naja Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000505673 Scintilla Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 101150010415 eat-5 gene Proteins 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A health-care product in the form of softgel for supplementing omega-3 fatty acid, lecithin and VE to human body, regulating blood fat, relaxing fatty liver, delaying senility, preventing sanile dementia, etc features that it contains proportionally alpha-linolenic acid, lecithin and VE.
Description
[technical field]
The present invention relates to a kind of compound formulation that contains alpha-linolenic acid free acid, soybean phospholipid and vitamin E.
[background technology]
Increasing along with affluenza patients such as hypertension, diabetes, a lot of people begin to eat fat less as far as possible, even suffer from " fearing fat disease ".Yet, on health of a few days ago holding and linolenic acid expert forum, medical experts such as the expert advisor of World Health Organization (WHO), the professor Wang Lan of HSPH of Fudan University point out, the more essential fatty acids of people's human body, can prevent multiple chronic disease as linolenic acid, and repulsion simply, frightened fatty is unfavorable for health on the contrary.Wang Lan points out, an amount of fat for normal physiology of human body and psychological need, is considerable, especially human body one of can't self synthetic essential fatty acid linolenic acid.Modern medicine study confirms, lacks alpha-linolenic acid, can bring out hyperlipidemia, diabetes, arteriosclerosis, cancer, cross various modern diseasies such as presenility, and lacking gamma-Linolenic acid, then can to cause the human endocrine metabolic mechanism to occur significantly disorderly.
Professor Zhao Fa of The 2nd Army Medical College represents, alpha-linolenic acid can be used as a kind of blood thinners, be applied to cardiovascular health, gamma-Linolenic acid then can be widely used in prevention and health care, as blood pressure lowering, anticancer, prevention breast tumor and premenstrual syndrome, dermatosis and beauty treatment, adjusting immunologic function etc.The generation of cardiovascular and cerebrovascular disease, tumor etc. and human diet custom and abnormalities of sugar/lipid metabolism are closely related.The ratio of gamma-Linolenic acid and alpha-linolenic acid has substantially exceeded in the modern diet structure normal ratio, and the too much absorption of gamma-Linolenic acid is to cause that blood fat is unbalance, the main cause of cardiovascular and cerebrovascular disease, needs to replenish a certain amount of alpha-linolenic acid.
Alpha-linolenic acid is to maintain the life core substance that human brain is evolved.It can suppress thrombosis sexually transmitted disease (STD) disease effectively, and prevention myocardial infarction and cerebral infarction, bring high blood pressure down at blood fat reducing, suppress hemorrhagic apoplexy, suppress the generation and the transfer of cancer, have growth intelligence, vision protection, effects such as slow down aging.
The most important physiological function of alpha-linolenic acid is that at first it is the parent of the serial polyunsaturated fatty acid of ω-3, and metabolism can generate DHA and EPA in vivo.The physiological function of alpha-linolenic acid shows in the control to cardiovascular disease that Germany, Japan bring into play the patent of its effect as medicine or supplement with regard to useful alpha-linolenic acid.Berry and Hirsch just by the fatty acid compositional analysis in the fatty tissue of one group not being in the mood for disease of ZANG-organs or hypertensive middle aged man, pointed out the every increase by 1% of alpha-linolenic acid in the fatty tissue in 1987, and tremulous pulse shrinks and diastolic pressure just reduces 667Pa.After 1988, people such as Salonen observe the lower blood pressure of Finland man to be had important related with alpha-linolenic acid absorption level.The Chinese Academy of Medical Sciences tests the hyperlipidemia of Mus with the Fructus Perillae oil that is rich in alpha-linolenic acid and shows that alpha-linolenic acid can obviously reduce T-CHOL and LDL-cholesterol levels in the serum, improves HDL-cholesterol/LDL-cholesterol ratio, and effect is better than clofibrate.
1993, FAO (Food and Agriculture Organization of the United Nation) and World Health Organization (WHO) united and issue a statement: in view of the importance and the human situation that generally lacks of alpha-linolenic acid, and worldwide special alpha-linolenic acid and the metabolite thereof promoted of decision.
1994, the contrast test in 5 years has by a definite date been carried out to the myocardial infarction survivor in the Lyons, France, and it is surprised that the result makes us: after 27 months, the monitoring group has 16 examples because of the death of having a heart attack, test group has only 3, and it is (17: 5) more than 3 times of test group that non-fatal myocardial infarctions outbreak is organized in monitoring.These data show, the margarine that is rich in alpha-linolenic acid can make painstaking effort seizure of disease and mortality rate reduce by 70%, and this result be do not take to bring high blood pressure down and the situation of serum lipids under obtain.Except above-mentioned famous test, the meals that many researcheres have also been reported alpha-linolenic acid or have been rich in alpha-linolenic acid have the effect of blood fat reducing, preventing thrombosis.
Another critical function that alpha-linolenic acid is observed is the enhancing human body immunity effect.Many animal test results show that alpha-linolenic acid has certain inhibitory action to breast carcinoma, colon cancer, pulmonary carcinoma and renal carcinoma.
Also prevent skin aging, slow down aging, antianaphylaxis and promote the research of aspects such as hair growth to report that these wherein a lot of tests are relevant as the meals source with the functional grease resource that is rich in alpha-linolenic acid relevant for alpha-linolenic acid.As the 5th long-lived township, the internationally recognized world---alpha-linolenic acid content is up to 25.2% in the geographic Speciality Foods Fructus Cannabis oil of China Guangxi crust horse, the Ministry of Public Health expert of the mystery of research this area longevity thinks that these characteristic meals are life-prolonging key factors, and alpha-linolenic acid has effect of prolonging life.
October 26 calendar year 2001, Beijing Youth Daily's published article, along with aged tendency of population and aging, senile dementia will become one of 21 century threat the most serious human disease, and in the U.S., the senile dementia death toll accounts for the 4th of old people's cause of the death.10% dementia of suffering from is in various degree arranged among China 1.3 hundred million old men approximately, have a strong impact on old people's health.Though the cause of disease of senile dementia is also not clear, strengthen the nutrition and health care of cerebral tissue, to reducing and delay some effects that have of senile dementia, the a-linolenic acid then is the important nutrient of old people's brain-strengthening.
The world health organisation recommendations human body dosage of dose alpha-linolenic acid day by day is 1.25g/ days.Therefore, we adopt the mode of taking for twice to replenish alpha-linolenic acid, and each taking dose is 625mg.
Vitamin E is a kind of basic nutrition element, and exact function is still not clear, belongs to antioxidant, can prevent film and other cyto-architectural multivalence unsaturated fatty acids in conjunction with the selenium in the food, makes and avoids radical damage; The protection erythrocyte avoids haemolysis, and neuroprotective and muscle are avoided oxygen free radical injury, keep the normal development and the function of nerve, muscle.Also may be the cofactor of some enzyme system.
Frenchman Gohley found lecithin (lecithin) from egg yolk in 1844, and with Greek called after Lecithos (lecithin), English Lecithin by name.Lecithin is the basic substance of life, and the human life be unable to do without its nourishing and protection from start to finish.Lecithin is present among each cell, more is to concentrate on vitals such as brain and nervous system, blood circulation, immune system and liver, the heart, kidney.The needed lecithin of life on a small quantity can be by hepatic secretion, but after 30 years old, and the lecithin of human body relies on from food picked-up basically and replenishes.
Though liver synthesizes a spot of lecithin, some important effect such as enzyme in its storing energy, drainage refuse, the supplying needs to consume a large amount of phospholipid, if lack lecithin, ethanol and hypercholesterolemia are easy to cause fatty liver and hepatitis and liver cirrhosis.Lecithin has antialcoholism action and emulsification, and the hepatocyte that can adequately protect can also promote hepatocellular activation and regeneration simultaneously, strengthens liver function.So reasonably replenish the prevalence that lecithin can effectively reduce diseases such as alcoholic cirrhosis, liver fat liver.
Lecithin has powerful emulsification, can make neutral fat and cholesterol decomposition is harmless scintilla, makes it to enter metabolic process, and is dissolved in the water and excretes, by emulsification, can reduce cholesterol, blood fat in the blood, make blood circulation unblocked.Lecithin has good hydrophilicity and lipophile, the choline and the acetyl of lecithin is combined into " acetylcholine " and can be brain sufficient nerve conduction material is provided, and has blood lipid regulation, alleviates health-care effects such as fatty liver, beauty treatment, improving memory, prevention senile dementia so a lot of people knows lecithin.
Lecithin all has certain content in foods such as egg yolk, Semen Glycines, frumentum, small fish, animal livers, Anguillar japonica, red Agkistrodon halys, Naja, safflower oil, Semen Maydis oil, Helianthi, but more complete still Semen sojae atricolor, egg yolk and the animal livers of nutrition and content.Lecithin is thermo-labile, and is active the most effective about 25 degrees centigrade, surpass 50 degrees centigrade after its activity lost most, therefore, be not easy very much during cooking food to obtain.Such as: every Semen Glycines approximately contains 1.3%～2.1% lecithin, and 900 kilograms of Semen Glyciness can only be extracted 2.3 kilograms granule lecithin.If need absorb 3 gram soybean phospholipids every day, must eat 5～6 kilograms of Semen Glyciness.Only way just is to use high-purity soybean lecithin to satisfy intake day by day.
From the extensive use of present stage phospholipid, production and development see that phospholipid has been described as the nutritional health food of human 21 century by people.Soybean phospholipid has become important the nutritional health food U.S., Europe and Japan and other countries in fashion now.
In the existing soybean lecithin graininess goods of Australia and " lecithin ball " (every heavy 600mg wherein contains crude soya bean lecithin 500mg, crude soya bean quintessence oil 50mg, natural fresh Oleum Cocois 50mg), be used as nutritional health food and export China.
Some countries in West Europe, many people will use the refined edible phospholipid of 10g～15g to be used as the nourishing healthy of self every day.Produced in USA have " natural phosphatidyl choline ball " (its main component: 1200mg/ grain, every contains 200mg crude soya bean lecithin), and outlet China.
By U.S. food and the approval of medicine administration commission, all replenish soybean lecithin in all infant recipes in right amount, at present to promote the brain development and the intelligence development of infant.
[summary of the invention]
The purpose of this invention is to provide a kind of compound formulation that can make things convenient for the alpha-linolenic acid free acid, soybean phospholipid and the vitamin E that satisfy the daily required intake of people simultaneously.
Technical scheme of the present invention is: a kind of compound formulation that contains alpha-linolenic acid free acid, soybean phospholipid and vitamin E, the weight ratio of three kinds of compositions are 625: 100: 100.
The present invention whenever says the material that must replenish according to above-mentioned three-type-person's body, pharmaceutical technology with the modern times prepares a kind of suitable for oral administration ground compound soft capsule preparation that contains alpha-linolenic acid free acid, soybean phospholipid, vitamin E, wherein the weight ratio of alpha-linolenic acid free acid, soybean phospholipid, vitamin E is 625: 1 00: 100, and add suitable medicinal or edible adjuvant and make gelatin soft capsule, have blood lipid regulation, alleviate health-care effects such as fatty liver, beauty treatment, improving memory, slow down aging, prevention senile dementia.
The alpha-linolenic acid free acid that the present invention relates to is highly purified alpha-linolenic acid free acid (purity is 70%～80%).
The soybean phospholipid that the present invention relates to is refining soybean phospholipid (lecithin content 〉=98%).
The vitamin E that the present invention relates to is medicinal or the food grade vitamin E.
The soybean phospholipid that the present invention relates to is food grade for making with extra care soybean phospholipid (containing lecithin 〉=98%) as formula material.
This compound formulation that the present invention relates to also contains a certain amount of other medical or edible batchings, as: medicinal, edible adjuvants such as PEG400, Tween 80, glycerol, gelatin, deionized water.
The dosage form of this compound formulation that the present invention relates to is a gelatin soft capsule, every capsules content 100mg～2000mg, and the weight ratio that every capsules contains alpha-linolenic acid free acid, refining soybean phospholipid, vitamin E is 625: 100: 100, other right amount of auxiliary materials.
The preparation method of compound formulation involved in the present invention is as follows: Tween 80 is sneaked in the liquid macrogol 400 of 10～100 times of amounts, stir, the weight ratio that is 625: 100: 100 then by weight adds alpha-linolenic acid free acid, refining soybean phospholipid, vitamin E, fully mix, with colloid mill or the abundant homogenizing of homogenizer, according to the soft capsule preparation method, utilize gelatin, glycerol to be capsule wall then, make soft capsule.
[specific embodiment]
Following example is used to illustrate the present invention, but should not be considered as restriction of the present invention.
Example:
Take by weighing:
High-purity alpha-linolenic acid free acid: 625mg
Vitamin E: 100mg
Soybean phospholipid: 100mg
PEG400: 400mg
Tween 80: 10mg
Tween 80 is sneaked in the liquid macrogol 400, stir, add alpha-linolenic acid free acid, refining soybean phospholipid, vitamin E then, fully mix, with colloid mill or the abundant homogenizing of homogenizer, according to the soft capsule preparation method, utilize gelatin, glycerol to be capsule wall then, make soft capsule.
Claims (3)
1. compound formulation that contains alpha-linolenic acid free acid, soybean phospholipid and vitamin E is characterized in that the weight ratio that said preparation contains alpha-linolenic acid free acid, soybean phospholipid and vitamin E is 625: 100: 100.
2. the compound formulation that contains alpha-linolenic acid free acid, soybean phospholipid and vitamin E according to claim 1 is characterized in that also containing at least a following adjuvant: PEG400, Tween 80, glycerol, gelatin, deionized water.
3. according to claim 1, the 2 described compound formulations that contain alpha-linolenic acid free acid, soybean phospholipid and vitamin E, the dosage form that it is characterized in that this compound formulation is a gelatin soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510052256 CN1679593A (en) | 2005-02-04 | 2005-02-04 | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510052256 CN1679593A (en) | 2005-02-04 | 2005-02-04 | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1679593A true CN1679593A (en) | 2005-10-12 |
Family
ID=35066602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510052256 Pending CN1679593A (en) | 2005-02-04 | 2005-02-04 | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1679593A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849990A (en) * | 2009-03-31 | 2010-10-06 | 北京因科瑞斯医药科技有限公司 | Pharmaceutical composition with function of improving memory and preparation method thereof |
| CN103238845A (en) * | 2013-05-31 | 2013-08-14 | 烟台燕园科玛生物技术开发有限公司 | Health food for strengthening brain and improving intelligence |
| CN103301194A (en) * | 2012-03-13 | 2013-09-18 | 朱凯 | Preparation technology of cold-pressed perilla seed oil capsule and its product |
| CN114680336A (en) * | 2020-12-30 | 2022-07-01 | 云南汉盟制药有限公司 | Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof |
-
2005
- 2005-02-04 CN CN 200510052256 patent/CN1679593A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849990A (en) * | 2009-03-31 | 2010-10-06 | 北京因科瑞斯医药科技有限公司 | Pharmaceutical composition with function of improving memory and preparation method thereof |
| CN103301194A (en) * | 2012-03-13 | 2013-09-18 | 朱凯 | Preparation technology of cold-pressed perilla seed oil capsule and its product |
| CN103238845A (en) * | 2013-05-31 | 2013-08-14 | 烟台燕园科玛生物技术开发有限公司 | Health food for strengthening brain and improving intelligence |
| CN114680336A (en) * | 2020-12-30 | 2022-07-01 | 云南汉盟制药有限公司 | Drop containing fructus cannabis unsaturated fatty acid and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6652891B2 (en) | Co-enzyme Q10 dietary supplement | |
| KR101809172B1 (en) | Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component | |
| US6743930B2 (en) | Kernel oil from plant kernel, process for extracting same, pharmaceutical composition and thereof | |
| CN105341185A (en) | Composite nutritional blend oil and preparation method thereof | |
| Amawi et al. | Effect of Lepidium sativum on lipid profiles and blood glucose in rats | |
| CN103156198A (en) | Fish oil soft capsules and preparation method thereof | |
| PT755633E (en) | BIPHASIC PREPARATION | |
| CN108835262A (en) | A kind of modulation milk powder and preparation method thereof improving memory | |
| US20050014825A1 (en) | Preparation and use of solidified oils | |
| CN101507766A (en) | Preparation method of traditional Chinese medicine capsules with blood-fat reduction and health-care function and use thereof | |
| CN101185706B (en) | Hippophae rhamnoides nutrition mixture with delaying senility function and preparation technique thereof | |
| WO2023213325A1 (en) | High-energy beverage prepared by combining and synergistically refining ultra-high-purity octacosanol-flavonoid compound and deuterated water, and preparation method therefor | |
| US8653130B2 (en) | Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s) | |
| US6313167B1 (en) | Composition having capability of removing risk factor during exercise | |
| KR20140028293A (en) | A pharmaceutical composition comprising the combined extract of crataegi fructus and citri pericarpium for treating or preventing obesity or lipid-related metabolic disorder | |
| CN1421208A (en) | Compound prepn containing alpha-linolic acid, lecithin and ginkgetin | |
| CN1679593A (en) | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E | |
| CN103169765A (en) | Eucommia ulmoides seed oil and red rice compound soft capsule preparation and preparation method thereof | |
| Yang et al. | Effect of combined extract of safflower seed with herbs on blood glucose level and biochemical parameters in streptozotocin-induced diabetic rats | |
| Lee | Essent ial Fat ty Acids | |
| CN1201611A (en) | Health food macte from cereal, vegetable and fruit | |
| WO2014134834A1 (en) | Composition and food comprising same and preparation method of food | |
| CN103690821A (en) | Composition for assisting in reducing blood fat | |
| CN103933146A (en) | Pollen product capable of adjusting human body immunity | |
| CN107372861B (en) | Composition and application thereof in preparation of product for improving hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |